No. 11 of Korean new drug for B hepatitis approved.

Published: 2006-11-15 07:00:00

Updated: 2006-11-15 07:00:00

Bukwang said that as of Nov. 13 the KFDA approved Lebovir 10mg cap (clevudine) for the treatment of chronic B hepatitis, which will become the number 11 of new drug solely developed by a Korean drug company, and the 4th innovative drug in the world.

Bukwang started its R&D in 1995 when none of anti-hepatitis drugs were available in the world markets by investing about 90 billion won f...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.